Dietary Supplement Adverse Event Reporting: Requirements and Process

What Is a Serious Adverse Event?

The Dietary Supplement and Nonprescription Drug Consumer Protection Act (Public Law 109-462, codified at 21 U.S.C. §379aa-1) defines a "serious adverse event" as any adverse event that results in:

• Death
• A life-threatening experience — The consumer was at immediate risk of death at the time of the adverse event
• Inpatient hospitalization — Admission to a hospital (does not include emergency room visits that do not result in admission)
• A persistent or significant disability or incapacity
• A congenital anomaly or birth defect
• An event requiring medical or surgical intervention to prevent one of the above outcomes — based on appropriate medical judgment

An "adverse event" is any health-related event associated with the use of a dietary supplement. Not all adverse events are "serious." Mild gastrointestinal upset from a supplement, for example, is an adverse event but likely not a "serious" adverse event. However, if that same gastrointestinal upset requires hospitalization, it becomes a serious adverse event requiring mandatory reporting.

The determination of whether an event qualifies as "serious" should be made based on the information available at the time of the report. You do not need to prove causation — the event need only be "associated with" supplement use.

The 15-Business-Day Reporting Requirement

When a responsible person receives a report of a serious adverse event, they must submit the report to FDA within 15 business days. The clock starts when the responsible person (or any agent or employee of the responsible person) first receives the adverse event information.

Key timing details:

• "Business days" means Monday through Friday, excluding federal holidays
• Day 1 is the day after receipt. If you receive an AE report on a Monday, Tuesday is Day 1 of your 15-day clock
• Receipt by anyone counts. If a customer service representative receives an adverse event report, the clock starts at that point — not when it reaches your regulatory or quality team
• All channels count. Adverse events received via phone, email, social media, website contact forms, Amazon reviews, retail partners, or any other channel trigger the reporting obligation

The responsible person is the entity whose name appears on the product label as the manufacturer, packer, or distributor. For private label products, this is typically the brand owner, not the contract manufacturer.

How to Submit: MedWatch Form 3500A

Serious adverse event reports for dietary supplements must be submitted to FDA using MedWatch Form 3500A (the mandatory reporting form for industry). This is different from Form 3500, which is the voluntary reporting form for healthcare professionals and consumers.

The 3500A form requires the following information:

• Patient information: Age, gender, weight (if available). The patient's identity is kept confidential by FDA.
• Adverse event description: A narrative description of the event, including onset date, duration, outcome, and any medical treatment received
• Product information: Product name, manufacturer, lot/batch number (if known), dosage, frequency, and duration of use
• Reporter information: Who reported the event (consumer, healthcare provider, etc.) and contact information
• Responsible person information: Company name, contact information, and report date

Submissions can be made electronically through the FDA Safety Reporting Portal (SRP) at safetyreporting.hhs.gov, or by mailing the completed form to FDA. Electronic submission is strongly recommended for faster processing and reliable delivery confirmation.

Along with the MedWatch form, you must include a copy of the product label (including the Supplement Facts panel) as it appeared at the time of the adverse event.

Follow-Up Reports

The initial 3500A submission is not the end of your reporting obligation. The statute requires that you submit follow-up information that becomes available within 1 year of the initial report:

• New medical information: If the consumer provides additional medical records, test results, or outcome information after the initial report, you must submit an updated report
• Product investigation results: If you conduct testing on the product (e.g., retained samples) and discover contamination, incorrect potency, or other issues, these findings must be reported
• Additional events from the same consumer: If the consumer reports additional symptoms or a worsening condition related to the same product use, this constitutes follow-up information

Follow-up reports are submitted on the same MedWatch 3500A form, referencing the original report number assigned by FDA. There is no specific timeline for follow-up reports beyond the 1-year window, but they should be submitted promptly as new information becomes available.

Record Retention: 6-Year Requirement

The Consumer Protection Act requires responsible persons to maintain records related to all adverse event reports — including non-serious adverse events — for a minimum of 6 years. This is one of the longest record retention requirements in FDA-regulated product categories.

Records that must be retained include:

• All adverse event reports received — both serious (which are reported to FDA) and non-serious (which are not mandatorily reported but must be kept on file)
• MedWatch 3500A forms submitted to FDA — copies of all mandatory reports filed
• Follow-up reports — all additional information submitted to FDA
• Internal investigation records — documentation of any investigation conducted in response to an adverse event
• Communication records — correspondence with consumers, healthcare providers, or FDA related to adverse events

FDA may inspect these records at any time. During an FDA inspection of a dietary supplement facility, adverse event records are among the most commonly requested documents. Incomplete or missing records can result in FDA Form 483 observations and potential warning letters.

Voluntary vs. Mandatory Reporting

The dietary supplement adverse event reporting system has both mandatory and voluntary components:

Important distinction: While only serious adverse events must be reported to FDA, the responsible person must retain records of all adverse events (including non-serious ones) for 6 years. This means you need a system for receiving, documenting, and classifying every adverse event — not just the serious ones.

Setting up a proper adverse event reporting system should be part of your overall dietary supplement compliance program, alongside 21 CFR Part 111 cGMP compliance and proper FDA facility registration. Foreign manufacturers should also ensure they have a designated U.S. Agent to receive FDA communications related to adverse event inquiries.